Wanlong Wu

9PUBLICATIONS
14CO-AUTHORS
Economic models and forecastingGene and molecular therapyAllergyMolecular targetsOther education not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jan 27, 2026
1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.

Xiao Huan, Ran Chen, Lei Jin

|Jul 14, 2025
Reply: Tofacitinib is a step forward for management of patients with interstitial lung disease associated with anti-MDA5-positive dermatomyositis.

Wanlong Wu, Shuang Ye

|Jan 30, 2025
Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study.

Wanlong Wu, Bingpeng Guo, Wenjia Sun

|Oct 18, 2023
Janus kinase inhibitor for anti-transcription intermediary factor 1-γ positive cancer-associated dermatomyositis.

Wanlong Wu, Jinju Chen, Linling Zhu

|Jul 07, 2023
Sarcoidosis presented as nodular myopathy.

Jia Li, Wanlong Wu, Zhixin Xue

|Jun 05, 2023
[

Jia Li, Weijun Wei, Wenwen Xu

Pageof 2

Frequent Collaborators

2 joint publications

Jia Li

2 joint publications

Shuang Ye

1 joint publications

Yi Chen

1 joint publications

Wenwen Xu